Indications
Stroke
For the treatment of hypertension, to lower blood pressure:
In patients not adequately controlled with ARB monotherapy
As initial therapy in patients likely to need multiple drugs to help
To achieve blood pressure goals and to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
Dosage And Administration
The recommended starting dose is 40/12.5 mg taken orally once daily. Most of the antihypertensive effect is apparent within 1 to 2 weeks. This combination may be used to provide additional blood pressure lowering for patients not adequately controlled on ARB or diuretic monotherapy treatment. Patients not controlled with azilsartan medoxomil 80 mg may have an additional systolic/diastolic clinic blood pressure reduction of 13/6 mm Hg when switched to this combination 40/12.5 mg.
This combination may be used as initial therapy if a patient is likely to need multiple drugs to achieve blood pressure goals. Patients titrated to the individual components (azilsartan medoxomil and chlorthalidone) may instead receive the corresponding dose of This combination.
Side Effects
The following potential adverse reactions are-
Fetal toxicity
Hypotension in Volume- or Salt-Depleted Patients
Impaired Renal Function
Hypokalemia Hyperuricemia
Precautions And Warnings
In patients with an activated renin-angiotensin-aldosterone system (RAAS), such as volume- and/or salt-depleted patients, this combination can cause excessive hypotension. Correct volume or salt depletion prior to administration of azilsartan and chlorthalidone.
In patients with renal artery stenosis, This combination may cause renal failure.
Monitor renal function in patients with renal impairment. Consider discontinuing this combination with progressive renal impairment.
Heart rhythm problems (e.g., bradycardia, QT prolongation, ventricular tachycardia), liver problems, certain uncorrected mineral imbalances (low potassium/magnesium levels), severe kidney problems.
Pregnancy And Lactation
Pregnancy Category D. Use of drugs that affect the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.